Navigation Links
New Data Analyses from Lorcaserin Phase 3 Clinical Trials to be Presented at Obesity 2011
Date:9/26/2011

of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the timing of regulatory review and approval is uncertain; the risk that data and other information related to Arena's research and development programs may not meet safety or efficacy requirements or otherwise be sufficient for regulatory approval; Arena's response to the CRL for the lorcaserin NDA or submission of a Marketing Authorization Application for regulatory approval of lorcaserin may not be submitted when anticipated, if at all; the FDA may request other information prior to or after Arena submits such response or approval of the lorcaserin NDA; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner expected or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena's filings with the Securities and Exchange Commission. These forward-looking statements represent Arena's judgment as of the time of this release. Arena disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.Contact
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
5. New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG
6. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting
7. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
8. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
9. Independent Analyses of the SEAS, SHARP and IMPROVE-IT Studies of Ezetimibe
10. New Analyses Indicate that Divigel(R) (estradiol gel) 0.1% Is a Valuable Option for Certain Postmenopausal Women With Hot Flashes
11. Results and Additional Analyses From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Heart Failure Congress 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... August 29, 2014 According ... Product & Services (Equipment, Reagent, Primer, Probe, Custom ... PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) - ... global Oligonucleotide Synthesis Market is expected to reach ... 2014, growing at a CAGR of 9.8% from ...
(Date:8/29/2014)... 29, 2014  In part four of ... hospital pharmacy as a strategic asset, Mary Baxter, ... for Cardinal Health,s Innovation Delivery Solutions business, discusses how ... both hospitals and patients. "Every hospital pharmacist ... of their job in a value-based healthcare world," Baxter ...
(Date:8/29/2014)... -- Research and Markets  has announced the addition ... Market 2014-2018" report to their offering. ... that connect, support, or surround bones. There are several ... cartilage, fascia, and other fibrous tissues. Repetitive use, accidents, ... result in wear and tear in these tissues. Orthopedic ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3
... Phosphagenics,Limited (ASX: POH, AIM: PSG, OTCQX: PPGNY) today ... undertake a Phase 1 transdermal,oxycodone clinical trial aimed ... management product. Phosphagenics has submitted all necessary ... be conducted at CMAX - an independent clinical ...
... Phase 2 clinical development, PRINCETON, N.J., Sept. ... in the discovery and development of novel,small molecule ... 2a,clinical study of PS433540, the company,s lead internal ... receptor antagonist,(DARA) that is being developed as a ...
Cached Medicine Technology:Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 2Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 3Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 4Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA) 5
(Date:8/30/2014)... August 30, 2014 The Plastic Surgery ... New Jersey and even in the U.S. to provide ... inches off of patients’ waists with deep-tissue heating. , ... small sections, Vanquish is more inclusive to target large ... lay comfortably under panels about one inch away from ...
(Date:8/30/2014)... Tenn. (PRWEB) August 30, 2014 ... around the country for the past several years, ... Tennessee Hyperbaric Center have announced a scholarship program ... This announcement follows a meeting held this summer ... In recent years, reporters have shed light on ...
(Date:8/30/2014)... Insomnia causes disturbances in every aspect of ... unknowingly developed insomnia and the steps often used to return ... in to the show at this link: Dr. Carol ... August 30, and will be podcasted at this link ... DrCarolFrancisTalkRadio.com. , "Insomnia causes countless unrecognized complications. ...
(Date:8/30/2014)... Pittsburgh, PA (PRWEB) August 30, 2014 ... the result of a car accident," said one of ... constant muscle strain in her shoulder and neck area. ... we invented reduced pain and pressure, assisting in comfort ... for the patent-pending PILLOW CRADLE to support the head, ...
(Date:8/30/2014)... New York (PRWEB) August 30, 2014 ... company, Profit By Search announces the Labor Day ... the clients will surely get the complete services related ... as SEO professionals, Content Writers, and others do have ... to perfection that reflects in their work and since ...
Breaking Medicine News(10 mins):Health News:NJ Top Docs Presents, The Plastic Surgery Group 2Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Sleepless Nights, Exhausting Days, Mental Fog – Relief for Insomnia With Clinical Psychologist Dr. Carol Francis 2Health News:Profit By Search Announces Labor Day Discount on SEO Services 2
... pregnancy loss are often concerned that toxins within ... Questions posed by these couples to their health ... accurate information regarding the reproductive impact of potential ... available. ,Heavy metals such as lead ...
... company, is racing giant rivals to bring a pill ... set a new standard in arthritis treatment. Scios' ambitions ... little more than $1 billion. That's because the first ... injectable drugs could gain the lion's share of a ...
... have found that a diet high in cholesterol and animal ... cancer of the stomach and esophagus that has been increasing ... dietary fiber, dietary beta-carotene, folic acid, vitamin C and vitamin ... cancers. ,The rate of a specific type of ...
... is a disorder of the eye where cells in the ... over 60 years of age.A new study states that eating ... ,Researchers from the department of Clinical Nutrition looked at ... information about their diet, and any vitamin supplements they were ...
... ready-to-eat meals could lead to the resurgence of botulism ... have made botulism a rare problem in modern society. ... ready-to-eat foods// that are only refrigerated before sold could ... cases involve mistakes in home canning or smoking of ...
... shows there is some truth in the 'use it or ... It is long been believed that mental stimulation can protect ... Disease Centre in the US now reveal new evidence for ... Study, involving the cognitive health of older Catholic nuns, priests ...
Cached Medicine News:
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: